Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

Author's Avatar
Jul 11, 2022

Savara+Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022 to be held in-person and virtually, September 4-6, 2022 in Barcelona, Spain.